Status:
RECRUITING
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Detailed Description
inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history
Eligibility Criteria
Inclusion
- 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- Uncommon EGFR Mutant Advanced NSCLC
Exclusion
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Key Trial Info
Start Date :
March 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 24 2027
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT04324164
Start Date
March 24 2020
End Date
December 24 2027
Last Update
January 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yongchang Zhang
Changsha, Hunan, China, 410013